JBJoaquina Celebre Baranda

Joaquina Celebre Baranda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joaquina Celebre Baranda has a total of 275 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pancreatic Acinar Cell Carcinoma: A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities

    by Noor Farhoud, Raed Moh’D Taiseer Al-Rajabi, Joaquina Celebre Baranda, Haoran Li, Wei Zhang, Ravi Kumar Paluri, Ashish Manne, Prasad Dandawate, Weijing Sun, Anup Kasi

    Pancreatic acinar cell carcinoma (PACC) is a rare exocrine pancreatic malignancy accounting for approximately 1–2% of adult pancreatic neoplasms. Although historically grouped with pancreatic ductal adenocarcinoma (PDAC), accumulating evidence demonstrates that PACC represents a biologically distinct entity with unique clinical, pathologic, and molecular characteristics. Compared with PDAC, PACC more commonly presents as a large pancreatic mass, is less frequently associated with obstructive jaundice, and exhibits lower rates of KRAS mutations. Recent genomic studies have identified recurrent alterations involving DNA damage repair pathways, WNT/β-catenin signaling, and actionable kinase fusions, including BRAF and RAF1 rearrangements. In advanced disease, fluoropyrimidine- and platinum-based regimens appear to demonstrate greater activity than traditional gemcitabine-based approaches, although prospective comparative data are lacking. This review summarizes the current understanding of the epidemiology, clinical presentation, pathology, molecular landscape, treatment approaches, and prognostic factors associated with PACC. We highlight emerging opportunities for precision oncology and discuss ongoing challenges in the management of this uncommon pancreatic malignancy.

  • Enfortumab Vedotin in Patients With Previously Treated Advanced Breast Cancer in the Phase II EV-202 Study

    by Antonio Giordano, Arif Ali Awan, Justine Yang Bruce, Hope S. Rugo, Jennifer R. Diamond, Yelena Novik, Joaquina Baranda, Kei Muro, Makiko Ono, Rita Nanda, et al.

    PURPOSE: EV-202 (ClinicalTrials.gov identifier: NCT04225117 ) evaluated enfortumab vedotin (EV), a nectin-4–directed antibody-drug conjugate, in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) and triple-negative breast cancer (TNBC). METHODS: This open-label, multicohort, Phase II study included eligible adults with locally advanced or metastatic (la/m) BC who had progressed, relapsed, or discontinued for toxicity during or after ≥1 previous standard-of-care cytotoxic regimen in the incurable, unresectable la/m setting, and had not received >2 previous lines of cytotoxic therapy in the la/m setting. Patients had received previous endocrine treatment (HR+/HER2−) or PD-1/L1 inhibitor if eligible (TNBC). Patients received EV 1.25 mg/kg intravenously on days 1, 8, and 15 of 28-day cycles. The primary end point was investigator-assessed confirmed objective response rate (ORR) per RECIST v1.1. Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Forty-five women with HR+/HER2− BC received EV. Confirmed ORR and DCR were 15.6% and 51.1%, respectively. Median DOR, PFS, and OS were 7.23, 5.39, and 19.75 months, respectively. Twenty patients experienced grade ≥3 treatment-related adverse events (TRAEs), most commonly, rash maculopapular (n = 7, 16%), pruritus, and increased AST (both n = 3, 7%). Forty-two women with TNBC received EV. Confirmed ORR and DCR were 19.0% and 57.1%, respectively. Median DOR, PFS, and OS were 3.78, 3.52, and 12.91 months, respectively. Twelve patients experienced grade ≥3 TRAEs, most commonly, decreased neutrophil count (n = 3, 7%). CONCLUSION: Although EV showed antitumor activity in heavily pretreated HR+/HER2− BC and TNBC, efficacy did not meet the prespecified threshold. The safety profile was consistent with previous reports. A trend was not observed between nectin-4 and patient response.


  • Open Access

    Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers

    by K. Muro, K. Chin, S.B. Maron, F.S. Braiteh, S. Mitani, H. Hara, Y. Kuboki, M.F. Mulcahy, J.C. Baranda, F.P. Gardner, et al.


  • Open Access

    Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study

    by Kei Muro, Trevor Feinstein, Joaquina Baranda, Ioana Bonta, Noriko Yanagitani, Todd Gersten, Leena Gandhi, Toshihiro Kudo, Naomi Fujioka, Jason Kaplan, et al.


  • Open Access

    Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial

    by Qamar J. Khan, Colleen Bohnenkamp, Taylor E. Monson, Milind A. Phadnis, Lauren Clark, Holly E. Smith, Vinay Raja, Manana Elia, Anne O'DEa, Mark R. Fesen, et al.

    PURPOSE: In metastatic breast cancer (MBC), oral capecitabine prescribed at the US Food and Drug Administration (FDA)–approved dose of 1,250 mg/m 2 twice daily, 14 days on, 7 days off, is associated with poor tolerance. Mathematical models suggest that a fixed-dose (FD), dose-dense schedule may optimize efficacy. We conducted a randomized, open-label trial to compare the efficacy and tolerability of FD capecitabine, 1,500 mg twice daily, 7 days on, 7 days off (FD-7/7), with the FDA-approved dose and schedule (standard-dose [SD]-14/7). METHODS: Females with MBC and any previous lines of therapy were included. Patients were randomly assigned 1:1 to either FD-7/7 or SD-14/7. The primary end point was 3-month progression-free survival (PFS). Capecitabine-related toxicities were graded at each visit. RESULTS: Between October 2015 and April 2021, 153 patients were enrolled (n = 80 FD-7/7, n = 73 SD-14/7). The 3-month PFS was 63.1% (95% CI, 52.0 to 74.2) in the FD-7/7 arm and 67.2% (95% CI, 54.5 to 79.9) in the SD-14/7 arm. Restricted mean survival time was used to report estimates of effect. The PFS (restricted mean) at 33 months was 10.1 months (95% CI, 7.6 to 12.6) in the FD-7/7 arm compared with 9.1 months (95% CI, 6.6 to 11.7) in the SD-14/7 arm. The overall survival (restricted mean) at 80 months was 30.6 months (95% CI, 23.6 to 37.6) in the FD-7/7 arm versus 24.5 months (95% CI, 18 to 31.1) in the SD-14/7 arm. Toxicity-related treatment discontinuation occurred in 24 patients (32.9%) in the SD-14/7 arm compared with seven patients (8.8%) in the FD-7/7 arm ( P = .0002). Grade 2 to 4 toxicities occurred in 79.5% in the SD-14/7 arm compared with 37.5% in the FD-7/7 arm ( P < .0001). CONCLUSION: In MBC, FD capecitabine 1,500 mg twice daily on a 7/7 schedule has less toxicity and similar efficacy when compared with body surface area-based dosing on a 14/7 schedule.


  • Open Access

    Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

    by Joaquina C. Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean‐Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose de Miguel, et al.

    SAR439459 (SAR'459), a “second‐generation” human anti‐transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of SAR'459 ± cemiplimab (intravenous) in patients with advanced solid tumors. Increasing doses of SAR'459 were administered every 2 or 3 weeks (Q2W, Q3W) alone (Part 1A) or with 3 mg/kg cemiplimab Q2W or 350 mg Q3W (Part 1B). In Part 2A (dose expansion), melanoma patients were randomly (1:1) administered 22.5 or 7.5 mg/kg SAR'459. In Part 2B (dose expansion), 22.5 mg/kg SAR'459 and 350 mg cemiplimab Q3W were administered. The primary end points were maximum tolerated dose (MTD) or maximum administered dose (MAD; Part 1), preliminary antitumor activity (Part 2B), and optimal monotherapy dose (Part 2A). Twenty‐eight and 24 patients were treated in Parts 1A and 1B, respectively; MTD was not reached, MAD was 15 (Q2W) and 22.5 mg/kg (Q3W) alone and in combination, respectively. Fourteen and 95 patients, including 14 hepatocellular carcinoma (HCC) patients, were treated in Parts 2A and 2B, respectively. The population PK model yielded satisfactory goodness‐of‐fit plots and adequately described the observed data by a two‐compartment PK model with linear elimination. Objective responses were not observed in Parts 1 and 2A. In Part 2B, objective response rate was 8.4% and 7.1% across tumor types and the HCC cohort, respectively. The most frequent treatment‐emergent adverse effects were hemorrhagic events (43.5%), keratoacanthoma (6.8%), and skin neoplasms (6.2%). Fatal bleeding occurred in 21.4% HCC patients despite the implementation of mitigation measures. SAR'459 monotherapy and combination with cemiplimab appeared relatively safe and tolerable in limited number of patients in dose escalation. However, the study was discontinued due to the unclear efficacy of SAR'459 and bleeding risk, particularly in HCC patients.


  • Open Access

    The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

    by Aroog Khaliq, William Wesson, Emerson Logan, Carine Tabak, Muhammad Umair Mushtaq, Tara Lin, Joaquina Baranda, Leyla Shune, Al-Ola Abdallah, Joseph McGuirk, et al.


  • Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration

    by Alice N. Weaver, Wade T. Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S. Gordon, Kerry J. Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, et al.

    Cancer vaccines strive to induce robust, antigen‐targeted, T‐cell‐mediated immune responses but have struggled to produce meaningful regression in solid tumors. An autologous cell vaccine, SQZ‐PBMC‐HPV, was developed by SQZ Biotechnologies using microfluidic squeezing technology to load PBMCs with HPV16 E6 and E7 antigens in HLA‐A*02+ patients. The SQZ‐PBMC‐HPV‐101 Phase 1 trial (NCT04084951) enrolled patients with incurable HPV16+ cancers. Here, we present a post hoc analysis of the relationship between Posttreatment CD8+ T cell infiltration and patient outcomes. SQZ‐PBMC‐HPV was administered as monotherapy every 3 weeks. Tumor samples were collected pre‐dose and post‐dose 4 weeks after treatment start. Biomarkers including CD8, MHC‐I, E6, E7, GZMB, and Ki67 were evaluated by immunohistochemistry, immunofluorescence, and RNA in situ hybridization, and were correlated with clinical response, survival, and drug product composition. Eighteen patients had paired pre‐ and post‐dose biopsies. Six (33%) had an increase in CD8+ T cell density in tumor parenchyma between screening and C2D8. Patients with increased CD8+ T cell density had improved disease control rate (66.7% vs 16.7%) and median overall survival (606.5 days vs 170.0 days, p = 0.0078). Drug product was significantly enriched for higher T cells and lower monocytes in the increased CD8+ T cell density group. In patients with incurable HPV16+ solid tumors treated with SQZ‐PBMC‐HPV, an increase in CD8+ T cell density within the tumor parenchyma was associated with superior disease control rate and overall survival. The product composition for patients with increased CD8+ T cell density was enriched for T cells.


  • Open Access

    Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort

    by Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Weijing Sun, et al.

    CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results. 29 patients were evaluable. 100% had confirmed pMMR/MSS tumors. Primary endpoint was met with ORR of 27.6% (95% CI 12.7-47.2%). Secondary endpoints of 4-month PFS rate was 44.83% (95% CI 26.5-64.3%); and median OS was 9.1 months (95% CI 5.8-20.2). Grade≥3 TRAE occurred in 39%. In post-hoc analysis of patients with RAS wild type tumors, ORR was 50% and median PFS and OS were 6.3 and 21.5 months respectively. Exploratory spatial transcriptomic profiling of pretreatment tumors showed upregulation of VEGF and MET signaling, increased extracellular matrix activity and preexisting anti-tumor immune responses coexisting with immune suppressive features like T cell migration barriers in responders versus non-responders. Cabozantinib plus durvalumab demonstrated anti-tumor activity, manageable toxicity, and have led to the activation of the phase III STELLAR-303 trial.


  • Open Access

    Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients

    by Ian M. Freed, Anup Kasi, Oluwadamilola Fateru, Mengjia Hu, Phasin Gonzalez, Nyla Weatherington, Harsh Pathak, Stephen Hyter, Weijing Sun, Raed Al-Rajabi, et al.

    There is a high clinical unmet need to improve outcomes for pancreatic ductal adenocarcinoma (PDAC) patients, either with the discovery of new therapies or biomarkers that can track response to treatment more efficiently than imaging. We report an innovative approach that will generate renewed interest in using circulating tumor cells (CTCs) to monitor treatment efficacy, which, in this case, used PDAC patients receiving an exploratory new therapy, poly ADP-ribose polymerase inhibitor (PARPi)—niraparib—as a case study. CTCs were enumerated from whole blood using a microfluidic approach that affinity captures epithelial and mesenchymal CTCs using anti-EpCAM and anti-FAPα monoclonal antibodies, respectively. These antibodies were poised on the surface of two separate microfluidic devices to discretely capture each subpopulation for interrogation. The isolated CTCs were enumerated using immunophenotyping to produce a numerical ratio consisting of the number of mesenchymal to epithelial CTCs (denoted “Φ”), which was used as an indicator of response to therapy, as determined using computed tomography (CT). A decreasing value of Φ during treatment was indicative of tumor response to the PARPi and was observed in 88% of the enrolled patients (n = 31). Changes in Φ during longitudinal testing were a better predictor of treatment response than the current standard CA19-9. We were able to differentiate between responders and non-responders using ΔΦ (p = 0.0093) with higher confidence than CA19-9 (p = 0.033). For CA19-9 non-producers, ΔΦ correctly predicted the outcome in 72% of the PDAC patients. Sequencing of the gDNA extracted from affinity-selected CTC subpopulations provided information that could be used for patient enrollment into the clinical trial based on their tumor mutational status in DNA repair genes.